The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease
Authors' conclusion
AID is feasible and safe and compared with usual care provides superior glucose management in predominantly pre-frail people with diabetes complicated by advanced CKD.
Study context
- Population
- Adults ≥18 years with T1D or insulin-treated T2D and advanced chronic kidney disease (CKD) (stage 3b or higher, including dialysis); 5 tertiary hospitals in Australia, 1 in Denmarkcrossover
- Participants
- 40 adults
- Comparison
- Automated insulin delivery (AID) vs usual care with real-time continuous glucose monitoring (CGM)
- Primary endpoint
- Percentage TIR (3.9-10.0 mmol/l)
- Follow-up
- Final 3 weeks of each treatment period
Methodological detailsprospective, open-label, multicentre
- Prospective
- Open-label
- Multicentre
Primary result
As reported in the abstract
TIR (3.9-10.0 mmol/l) · end of each treatment period
P < 0.001
Further findings
Hyperglycaemic CGM metrics
- AID significantly improved all hyperglycaemic CGM metrics vs usual care
Frailty
- Participants were predominantly pre-frail at baseline and remained stable on-trial
Safety
Hypoglycaemia and adverse events · trial period
- Serious adverse events attributed to study devices
- 0
- Hospital admissions for medical issues unrelated to device use
- 25%
- Hypoglycaemia rates were unchanged
Original publication
The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease. Diabetologia. Published 11 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →